The-Ngoc Nguyen, MD
Family Medicine · Spring, TXNPI 1427257526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 42.8% of the total. Reporting peaked in 2019 at $154 and has fallen 58.1% since, to $65 in 2025. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 31 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$238
- Paratek Pharmaceuticals, Inc.$79
- Exact Sciences$66
- Genentech USA, Inc.$38
- Abbott$32
- Medtronic$22
- plus $81 from 5 others
What the payments were for
- Food & beverage$556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $238 |
| Paratek Pharmaceuticals, Inc. | 4 | $79 |
| Exact Sciences | 4 | $66 |
| Genentech USA, Inc. | 2 | $38 |
| Abbott | 2 | $32 |
| Medtronic | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| Antares Pharma, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$556 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 86 | $854 |
| Atorvastatin Calcium | 103 | $669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $653 |
| Metoprolol Succinate | 49 | $612 |
| Mirtazapine | 12 | $589 |
| Rosuvastatin Calcium | 67 | $541 |
| Tamsulosin Hcl | 51 | $512 |
| Metformin Hcl | 60 | $440 |
| Methylprednisolone | 104 | $436 |
| Pantoprazole Sodium | 30 | $374 |
| Pioglitazone Hcl | 36 | $368 |
| Azithromycin | 106 | $365 |
| Olmesartan Medoxomil | 13 | $349 |
| Montelukast Sodium | 34 | $332 |
| Temazepam | 41 | $314 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Spring
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.